BioVie logo

BioVieNASDAQ: BIVI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 September 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$37.48 M
-91%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector
-96%vs. 3y high
63%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 31 Oct 2024 23:58:04 GMT
$2.72-$0.10(-3.54%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

BIVI Latest News

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
globenewswire.com28 October 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
globenewswire.com28 October 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
globenewswire.com24 October 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share.

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com23 October 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Oct. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share, resulting in total gross proceeds of $6,000,750, before deducting the placement agent's fees and offering expenses.

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com21 October 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 4,443,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $1.50 per share, resulting in total gross proceeds of $6,664,500, before deducting the placement agent's fees and offering expenses.

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
globenewswire.com15 October 2024 Sentiment: POSITIVE

Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets

BioVie Inc. Announces Closing of Public Offering
globenewswire.com25 September 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of a previously announced best efforts public offering of 1,360,800 shares of its common stock, pre-funded warrants to purchase 600,000 shares of its common stock (“Pre-funded Warrants”) and warrants to purchase up to 1,960,800 shares of common stock (the "Common Warrants") at a combined public offering price of $1.53 per share (or Pre-funded Warrant) and associated Common Warrant. The Common Warrants have an exercise price of $1.53 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.

Crude Oil Gains Over 1%; BioVie Shares Plunge
benzinga.com24 September 2024 Sentiment: NEUTRAL

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday.

BioVie Inc. Announces Pricing of Public Offering
globenewswire.com23 September 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions.

BioVie Inc. Announces Proposed Public Offering
globenewswire.com23 September 2024 Sentiment: POSITIVE

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying common stock purchase warrants in a best efforts public offering. All of the shares of common stock (and/or Pre-Funded Warrants) and accompanying common stock purchase warrants are to be sold by the Company.

What type of business is BioVie?

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

What sector is BioVie in?

BioVie is in the Healthcare sector

What industry is BioVie in?

BioVie is in the Biotechnology industry

What country is BioVie from?

BioVie is headquartered in United States

When did BioVie go public?

BioVie initial public offering (IPO) was on 18 September 2020

What is BioVie website?

https://bioviepharma.com

Is BioVie in the S&P 500?

No, BioVie is not included in the S&P 500 index

Is BioVie in the NASDAQ 100?

No, BioVie is not included in the NASDAQ 100 index

Is BioVie in the Dow Jones?

No, BioVie is not included in the Dow Jones index

When was BioVie the previous earnings report?

No data

When does BioVie earnings report?

The next expected earnings date for BioVie is 08 November 2024